ALNYLAM PHARMACEUTICALS, INC. (ALNY) › Cash & EquivalentsALNYLAM PHARMACEUTICALS, INC. (ALNY) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2007-12-31: $105.16M2008-12-31: $191.79M2009-12-31: $137.47M2010-12-31: $74.60M2011-12-31: $70.23M2012-12-31: $51.41M2013-12-31: $53.17M2014-12-31: $75.18M2015-12-31: $180.90M2016-12-31: $193.62M2017-12-31: $645.36M2018-12-31: $420.15M2019-12-31: $547.18M2020-12-31: $496.58M2021-12-31: $819.98M2022-12-31: $866.39M2023-12-31: $812.69M2024-12-31: $966.43M2025-12-31: $1.66B$1.66B2007-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$1.66B+71.5%2026-02-12Balance as of period end2024-12-31$966.43M+18.9%2026-02-12Balance as of period end2023-12-31$812.69M-6.2%2026-02-12Balance as of period end2022-12-31$866.39M+5.7%2025-02-13Balance as of period end2021-12-31$819.98M+65.1%2024-02-15Balance as of period end2020-12-31$496.58M-9.2%2023-02-23Balance as of period end2019-12-31$547.18M+30.2%2022-02-10Balance as of period end2018-12-31$420.15M-34.9%2021-02-11Balance as of period end2017-12-31$645.36M+233.3%2020-02-13Balance as of period end2016-12-31$193.62M+7.0%2019-02-14Balance as of period end2015-12-31$180.90M+140.6%2018-02-15Balance as of period end2014-12-31$75.18M+41.4%2018-02-15Balance as of period end2013-12-31$53.17M+3.4%2017-02-15Balance as of period end2012-12-31$51.41M-26.8%2016-02-12Balance as of period end2011-12-31$70.23M-5.9%2015-02-13Balance as of period end2010-12-31$74.60M-45.7%2014-02-20Balance as of period end2009-12-31$137.47M-28.3%2013-02-19Balance as of period end2008-12-31$191.79M+82.4%2012-02-13Balance as of period end2007-12-31$105.16M—2011-02-18Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)